financetom
Business
financetom
/
Business
/
Synthetix Considers Purchase of Options Platform Derive in $27M Token-Swap Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Synthetix Considers Purchase of Options Platform Derive in $27M Token-Swap Deal
May 26, 2025 7:30 AM

Ethereum-based derivatives powerhouse Synthetix is considering buying options trading platform Derive in an token-for-token deal valued at $27 million that would see the project absorbed back into the protocol that gave it birth.

The proposal, SIP-415 on Synthetix and DIP on Derive, needs to be approved by both communities and would see Derive’s treasury, codebase and operational stack incorporated into Synthetix.

The deal marks a rare instance of a token swap-based acquisition in decentralized finance (DeFi ( DEFT )), and is being pitched as part of Synthetix's growing ecosystem. Derive (DRV) token holders would receive 27 newly issued SNX tokens for each DRV they own. The tokens are subject to a three-month lockup and nine-month linear vesting schedule. Synthetix would mint up to 29.3 million SNX, amounting to roughly 8.6% inflation of its current token supply.

Derive, originally Lyra, went live in 2021 and was spun out from Synthetix. It has previously moved away from the protocol, ending support for Synthetix’s sUSD stablecoin, switching to GMX for liquidity, and launching its own perpetual futures product.

Early responses from the Derive community showed dissatisfaction with the idea.

“I don´t see any benefit for Derive on it,” one commenter said. “In the other hand (sic), it all looks great and advantageous for Synthetix.”

Another user took aim at the proposed valuations.

“That exchange rate is a poor reflection of the value of derive as a platform,” commenter ‘Ramjo’ said. “And then have the nerve to put a long vesting period on it AS WELL.”

DRV prices are down 20% in the past 24 hours, data on CoinGecko shows, while SNX is up 7%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MOVES-Nextalia hires ex JPM banker to lead new private credit strategy
MOVES-Nextalia hires ex JPM banker to lead new private credit strategy
Sep 16, 2025
MILAN, Sept 16 (Reuters) - Italy's Nextalia has hired Enrico Monti, a former senior banker at JPMorgan ( JPM ) in London, to lead the private equity firm's new private credit strategy. He will join Nextalia as a partner, an update of Monti's LinkedIn profile showed. Monti had lately been the head of corporate banking at Rome-based Banca del Fucino,...
Lufthansa to propose Johannes Teyssen as supervisory board chief at upcoming AGM
Lufthansa to propose Johannes Teyssen as supervisory board chief at upcoming AGM
Sep 16, 2025
(Reuters) -Lufthansa said on Tuesday it would propose Johannes Teyssen to be elected as chair of the supervisory board at the airline's next general meeting in May 2026. He will succeed Karl-Ludwig Kley, who will step down from the airline's supervisory board after eight years as chair, the company added in a statement. (Reporting by Paolo Laudani; Editing by Emelia...
US parents to urge Senate to prevent AI chatbot harms to kids
US parents to urge Senate to prevent AI chatbot harms to kids
Sep 16, 2025
Sept 16 (Reuters) - Three parents whose children died or were hospitalized after interacting with artificial intelligence chatbots will testify before a U.S. Senate panel on Tuesday, as lawmakers grapple with potential safeguards around the technology. Matthew Raine, who sued OpenAI after his son Adam died by suicide in California after receiving detailed self-harm instructions from ChatGPT, is among those...
UK must spend more on medicines, minister says, as Big Pharma cuts investment
UK must spend more on medicines, minister says, as Big Pharma cuts investment
Sep 16, 2025
* Pharma industry halting UK investments * Science minister 'deeply concerned' by declining medicine spend * Industry says UK undervalues new drug innovation By Alistair Smout LONDON, Sept 16 (Reuters) - Britain needs to reverse its declining spend on medicines, science minister Patrick Vallance said on Tuesday, after two major pharmaceutical firms cancelled or paused investments and the industry warned...
Copyright 2023-2026 - www.financetom.com All Rights Reserved